Guest Editors
Fateeha Furqan, MD, The University of Texas at MD Anderson Cancer Center, USA
Guido Lancman, MD, Princess Margaret Cancer Centre, Canada
Submission Status: Open | Submission Deadline: October 31, 2025
Antibody-based cancer therapeutics
Meet the Guest Editors
Back to topFateeha Furqan, MD, The University of Texas at MD Anderson Cancer Center, USA
Guido Lancman, MD, Princess Margaret Cancer Centre, Canada
About the Collection
Antibody-based therapeutics have emerged as a transformative approach in the treatment of cancers, leveraging the specificity of antibodies to target and eliminate cancer cells via different modes of action while sparing healthy tissues. This Collection aims to explore the design, manufacture, and clinical aspects of diverse antibody-based therapies, including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and novel formats such as nanobodies and antibody fragments. These innovative treatments have shown promise in improving patient outcomes and have become integral components of modern cancer treatment regimens.
Enhancing our understanding of antibody-based cancer therapeutics is crucial for optimizing their efficacy and safety. Significant strides have been made in recent years, including the development of next-generation antibody-drug conjugates that enhance the targeted delivery of cytotoxic agents, as well as bispecific antibodies that engage multiple targets simultaneously. These advances have not only improved treatment responses but have also provided insights into overcoming resistance mechanisms. Continued research in this area will facilitate the identification of novel targets and the development of more effective therapeutic strategies.
As research in antibody-based cancer therapeutics progresses, we can anticipate exciting innovations, such as the integration of personalized medicine approaches that tailor therapies to individual patient profiles. Future advancements may also include the development of combination therapies that synergize the effects of antibody-based treatments with other modalities, such as chemotherapy, or other cancer medications, ultimately leading to improved survival rates and quality of life for cancer patients.
The Collection welcomes manuscripts in the areas of research including but not limited to:
- Development of (novel) antibody formats
- Biology and mechanisms of action
- Challenges associated with the manufacture and analytics
- Preclinical and clinical outcomes
- Efficacy and safety of antibody-based therapies
- Combination in therapies in combating cancers
- Mechanisms of resistance and clinical implications
- (Computer-assisted) target discovery and antibody design
In addition to original research, study protocols and clinical trials are also welcome for submission.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
This Collection supports and amplifies research related to SDG 3: Good Health & Well-being.
Image credit: © peterschreiber.media / Getty Images / iStock
There are currently no articles in this collection.
Submission Guidelines
Back to topThis Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Antibody-based cancer therapeutics" from the dropdown menu.
Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.
The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.